bluebird bio (BLUE) Q3 2024 earnings summary

Executive summary

• Achieved accelerated growth with 74 patient starts completed or scheduled in 2024, and 30 already scheduled for 2025, as commercial launches of ZYNTEGLO, LYFGENIA, and SKYSONA accelerate.

• Focused on U.S. commercialization of gene therapies; European marketing authorizations withdrawn.

• Net loss of $60.8M for Q3 2024 and $212.0M for the nine months ended September 30, 2024; accumulated deficit of $4.5B.

• Restructuring in September 2024 reduced workforce by 25% to cut cash operating expenses by ~20% by Q3 2025.

• Cash and cash equivalents of $70.7M as of September 30, 2024, expected to fund operations into Q1 2025; substantial doubt exists regarding ability to continue as a going concern.

Financial highlights

• Q3 2024 revenue was $10.6 million, down from $16.1 million in Q2 and $12.4 million in Q3 2023, with at least $25 million expected in Q4 2024.

• Nine months 2024 revenue: $45.3M, up from $21.7M in 2023, driven by increased product sales.

• Cost of product revenue increased to $11.8M in Q3 2024 (vs. $9.1M in Q3 2023).

• SG&A expenses remained consistent year-over-year; R&D expenses decreased by $36.1M due to reclassification to inventory and cost of goods.

• Net loss: $60.8M in Q3 2024, improved from $87.2M in Q3 2023; EPS of $(0.31) vs. $(0.80) year-over-year.

Outlook and guidance

• Expects quarterly cash flow break-even in H2 2025, assuming 40 drug product deliveries per quarter and additional financing.

• Revenue projected to rebound in Q4 2024 as more patients are infused.

• Cash runway expected into Q1 2025, pending further financing and cost-saving initiatives.

• Gross-to-net discounts for 2024 anticipated in the 20%-25% range, depending on product, payer mix, and outcomes-based agreements.

• Ongoing focus on U.S. commercialization; no new clinical trials planned in Europe.